Oral metformin transiently lowers post-prandial glucose response by reducing the apical expression of sodium-glucose co-transporter 1 in enterocytes

Metformin (MET) is the most prescribed antidiabetic drug, but its mechanisms of action remain elusive. Recent data point to the gut as MET’s primary target. Here, we explored the effect of MET on the gut glucose transport machinery. Using human enterocytes (Caco-2/TC7 cells) in vitro, we showed that...

Descripción completa

Detalles Bibliográficos
Autores principales: Zubiaga, Lorea, Briand, Olivier, Auger, Florent, Touche, Veronique, Hubert, Thomas, Thevenet, Julien, Marciniak, Camille, Quenon, Audrey, Bonner, Caroline, Peschard, Simon, Raverdy, Violeta, Daoudi, Mehdi, Kerr-Conte, Julie, Pasquetti, Gianni, Koepsell, Hermann, Zdzieblo, Daniela, Mühlemann, Markus, Thorens, Bernard, Delzenne, Nathalie D., Bindels, Laure B., Deprez, Benoit, Vantyghem, Marie C., Laferrère, Blandine, Staels, Bart, Huglo, Damien, Lestavel, Sophie, Pattou, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024157/
https://www.ncbi.nlm.nih.gov/pubmed/36942050
http://dx.doi.org/10.1016/j.isci.2023.106057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024157/
https://www.ncbi.nlm.nih.gov/pubmed/36942050
http://dx.doi.org/10.1016/j.isci.2023.106057

Ejemplares similares